KRAS G12D MUTATION
Clinical trials for KRAS G12D MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes on tough lung cancer mutation
Disease control Recruiting nowThis phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly a…
Matched conditions: KRAS G12D MUTATION
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug, RNK08954, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe and effective dose and see if the drug can shrink tumors or slow their growth. About 152 adults who have already tried stan…
Matched conditions: KRAS G12D MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC